新華製藥(00719.HK)克治療拉黴素片通過仿製藥一致性評價

You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.

Hong Kong

Open Account

新華製藥(00719.HK)克治療拉黴素片通過仿製藥一致性評價

阿思達克 06-30 08:23

新華製藥(00719.HK)(000756.SZ)公布近日收到國藥監局核准簽發的克拉黴素片(0.25g)《藥品補充申請批件》，該產品通過仿製藥質量和療效一致性評價。

克拉黴素是由紅黴素6位羥基選擇性甲基化製得的一種新型大環內酯類抗生素，臨床上主要用於治療由對克拉黴素敏感的致病菌引起的感染。

Customer Service Hotline︰+852 3018 4526

Email︰cs@usmarthk.com

Address︰26/F, 2606, 308 Des Voeux Road Central, Sheung Wan, Hong Kong

WhatsApp︰+852 5989 2641

Join the Community：

uSmart Securities Limited

is a licensed corporation approved by the Hong Kong SFC (CE number: BJA907), provides securities trading services and is subject to its supervision.

Market News

新華製藥(00719.HK)克治療拉黴素片通過仿製藥一致性評價

Services

About Us

Agreement Statement